Diarrhoea Predominant Irritable Bowel Syndrome Completed Phase 4 Trials for Rifaximin (DB01220)

Also known as: Diarrhea-predominant Irritable Bowel Syndrome / IBS, Diarrhea Predominant / Irritable Bowel Syndrome With Diarrhea / Diarrhea Predominant Irritable Bowel Syndrome / Diarrhea- Predominant Irritable Bowel Syndrome / Diarrhea Dominant Irritable Bowel Syndrome / Irritable bowel syndrome with diarrhea (disorder) / Irritable bowel syndrome without diarrhea / Irritable colon / Colitis mucous / Mucous colitis / Colon spastic / Spastic colon / Irritable colon syndrome / Functional bowel syndrome / Irritable bowel / Irritable bowel syndrome / Irritable colon (disorder)

IndicationStatusPhase
DBCOND0075933 (Diarrhoea Predominant Irritable Bowel Syndrome)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05867550To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With DiarrheaTreatment
NCT03557788Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel SyndromeBasic Science